Theravance BiopharmaTBPH
TBPH
About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Employees: 99
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more call options, than puts
Call options by funds: $6K | Put options by funds: $3K
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
30% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 33
15% more capital invested
Capital invested by funds: $369M [Q3] → $422M (+$53.5M) [Q4]
7% more funds holding
Funds holding: 119 [Q3] → 127 (+8) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
1.8% less ownership
Funds ownership: 94.11% [Q3] → 92.3% (-1.8%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
58%
upside
Avg. target
$15
58%
upside
High target
$15
58%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 25% 1-year accuracy 42 / 171 met price target | 58%upside $15 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 4 articles about TBPH published over the past 30 days
Neutral
PRNewsWire
1 day ago
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Neutral
PRNewsWire
5 days ago
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.
Neutral
PRNewsWire
3 weeks ago
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN , April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Both analyses were presented as platform presentations at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California.
Neutral
PRNewsWire
4 weeks ago
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.
Positive
Zacks Investment Research
1 month ago
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Neutral
PRNewsWire
1 month ago
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.
Positive
Zacks Investment Research
2 months ago
Theravance's Q4 Loss In Line With Estimates, Sales Beat
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Neutral
Seeking Alpha
2 months ago
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operator Ladies and gentlemen, good afternoon.
Neutral
Zacks Investment Research
2 months ago
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago.
Neutral
PRNewsWire
2 months ago
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study on track to enroll final patient in the open label portion by mid-2025 Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025 DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter and full-year ended December 31, 2024. "Theravance Biopharma ended 2024 on a high note, having collaborated closely with Viatris to deliver record fourth quarter YUPELRI net sales and profitability, while achieving $50 million in TRELEGY related sales milestones," said Rick E Winningham, Theravance Biopharma CEO.
Charts implemented using Lightweight Charts™